newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

  • Minerva Neurosciences, Inc. will host an in-person & virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET to discuss roluperidone for negative symptoms of schizophrenia.
  • The event will feature key opinion leaders Christoph Correll, MD, Brian Kirkpatrick, MD, & Gregory Strauss, PhD, alongside company management.
  • Key discussion topics include new analysis supporting roluperidone's efficacy & safety, updates on the ongoing Phase 3 trial, & other company news.
  • A live webcast & replay will be available via the Investors section of the company's website.
  • Roluperidone is an investigational monotherapy for treating negative symptoms of schizophrenia, an area with no current FDA-approved treatments.
  • Minerva is conducting a confirmatory Phase 3 trial to evaluate roluperidone for this indication.
  • The press release includes forward-looking statements regarding trial timelines, regulatory potential, & financial outlook, accompanied by standard risk factor disclosures.